Two-year effectiveness of erenumab in resistant chronic migraine: a prospective real-world analysis

Overview of attention for article published in The Journal of Headache and Pain, November 2022

Altmetric Badge

About this Attention Score

Good Attention Score compared to outputs of the same age (66th percentile)
Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter: 5 X users

Citations

dimensions_citation: 10 Dimensions

Readers on

mendeley: 18 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 8 X posts from 5 X users, with an upper bound of 28,071 followers.

RT @EHF_Official: Is #erenumab a suitable long-term treatment in patients with resistant-refractory #migraine? A real-world study showed th…

08 Dec 2022

Reply Repost Favourite

RT @ap_andreou: Sustained long-term efficacy of #CGRP mAb #erenumab in refractory chronic #migraine patients is low. https://t.co/8Y6qrOMs8…

05 Dec 2022

Reply Repost Favourite

Migren aşısı ve dirençli kronik migren tedavisindeki yeri konusunda fikir edinmek isteyenler için, okuduklarımdan ve kongreden dinlediklerimden çıkardığım sonuçları yazacağım:

24 Nov 2022

Reply Repost Favourite

RT @ap_andreou: Sustained long-term efficacy of #CGRP mAb #erenumab in refractory chronic #migraine patients is low. https://t.co/8Y6qrOMs8…

16 Nov 2022

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 4 additional X posts.